Navigation Links
The ASCO Post Publishes Multiple Perspectives on Outcome of ODAC Meeting Regarding Bevacizumab in Advanced Breast Cancer
Date:9/1/2010

COLD SPRING HARBOR, N.Y., Sept. 1 /PRNewswire/ -- The ASCO Post captured initial reactions to the Oncologic Drugs Advisory Committee (ODAC) recommendation that the breast cancer indication for bevacizumab (Avastin) be revoked in interviews with ODAC voting members, breast cancer specialists, oncologists in private practice, third-party payers, and a patient advocate. These reactions are available online now at ASCOPost.com and appear in the September issue of the publication.

"It is important that the breast cancer community rest assured that ODAC is an independent, unbiased panel of experts in oncology whose mission is to provide their best objective scientific and clinical recommendations to the FDA for drug approval," said ODAC Chair, Wyndham Wilson, MD, PhD. Dr. Wilson is Chief of the Lymphoid Therapeutics Section of the Center for Cancer Research, National Cancer Institute.

Bevacizumab is currently approved in combination with paclitaxel for the first-line treatment of advanced HER2-negative breast cancer, based on encouraging results of the E2100 trial (N Engl J Med 357:2666-2676, 2007). The FDA provisionally granted accelerated approval but requested confirmatory data from the manufacturer, Genentech. In November 2009, Genentech supplied the results of the AVADO (J Clin Oncol 28:3239-3247, 2010) and RIBBON-1 trials (J Clin Oncol 27(abstract 1005), 2009). On July 20, 2010, ODAC recommended against conversion to full approval.

Joanne Mortimer, MD, a member of ODAC, who voted to approve bevacizumab in advanced breast cancer in December 2007 based on the E2100 study, said, "The additional data from AVADO and RIBBON-1 supported an increased response rate, but also confirmed the increased toxicity and lack of survival advantage with bevacizumab. Like the majority of panel [ODAC] members, I could not recommend approval." Dr. Mortimer is Director of the Women's Cancers' Program and Professor of Medical Oncolo
'/>"/>

SOURCE Harborside Press
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. The New England Journal of Medicine Publishes Results of Landmark CREST Study, Showing Similar Positive Outcomes for Abbotts Carotid Stent System and Surgery
2. The Lancet publishes new data demonstrating superior efficacy of Victoza(R) (liraglutide [rDNA] injection) compared to Januvia(R) (sitagliptin) in the treatment of type 2 diabetes
3. BioTrends Publishes New Report Exploring Treatment Patterns for Anemia Across a Variety of Physician Specialties
4. NexBio(R) Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses
5. BIA Publishes White Paper: ISO 9000 Role in Document Review, Emphasizes Quality Equals Defensibility
6. United States Patent and Trademark Office Publishes Stemedicas Patent Application for the Treatment of Diabetic Retinopathy
7. The Lancet Publishes Direct Comparison Study Between Liraglutide and Exenatide
8. The Lancet Publishes Two-Year Results of Abbotts Fully Bioabsorbable Drug Eluting Stent
9. New England Journal of Medicine Publishes Results from Boston Scientifics Landmark SYNTAX(TM) Trial
10. Groundbreaking Paper Publishes Long Term Results of a Successful Phase I Clinical Trial Using Autologous Neural Stem Cells to Treat Parkinsons Disease
11. New England Journal of Medicine Publishes Results From the Landmark ATHENA Trial with Multaq(R) (dronedarone) in Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... PARIS , July 30, 2014 /PRNewswire/ ... Sanofi (EURONEXT: SAN and NYSE: SNY ) ... of alirocumab in people with hypercholesterolemia met their primary ... in low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared ... monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). ...
(Date:7/30/2014)... July 30, 2014  Packaging Coordinators, Inc. (PCI) is ... to acquire Penn Pharmaceutical Services Limited (Penn Pharma). Penn Pharma ... in the United Kingdom and ... and Tokyo , Japan. Penn ... Clinical and Commercial dosage form manufacturing, as well as ...
(Date:7/30/2014)... FOREST, Ill., July 30, 2014  Hospira, Inc. ... provider of injectable drugs and infusion technologies, today ... 30, 2014. Net sales for the quarter were ... were $0.72. (Adjusted* measures exclude specified items as ... attached schedules.) On a U.S. Generally Accepted Accounting ...
Breaking Medicine Technology:Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8PCI Announces Definitive Agreement to Acquire Penn Pharma 2PCI Announces Definitive Agreement to Acquire Penn Pharma 3PCI Announces Definitive Agreement to Acquire Penn Pharma 4PCI Announces Definitive Agreement to Acquire Penn Pharma 5Hospira Reports Second-Quarter 2014 Results 2Hospira Reports Second-Quarter 2014 Results 3Hospira Reports Second-Quarter 2014 Results 4Hospira Reports Second-Quarter 2014 Results 5Hospira Reports Second-Quarter 2014 Results 6Hospira Reports Second-Quarter 2014 Results 7Hospira Reports Second-Quarter 2014 Results 8Hospira Reports Second-Quarter 2014 Results 9Hospira Reports Second-Quarter 2014 Results 10Hospira Reports Second-Quarter 2014 Results 11Hospira Reports Second-Quarter 2014 Results 12Hospira Reports Second-Quarter 2014 Results 13Hospira Reports Second-Quarter 2014 Results 14Hospira Reports Second-Quarter 2014 Results 15Hospira Reports Second-Quarter 2014 Results 16Hospira Reports Second-Quarter 2014 Results 17Hospira Reports Second-Quarter 2014 Results 18Hospira Reports Second-Quarter 2014 Results 19Hospira Reports Second-Quarter 2014 Results 20Hospira Reports Second-Quarter 2014 Results 21Hospira Reports Second-Quarter 2014 Results 22Hospira Reports Second-Quarter 2014 Results 23Hospira Reports Second-Quarter 2014 Results 24Hospira Reports Second-Quarter 2014 Results 25
... COLLEGEVILLE, Pa., July 27 ... WYE ), announced the publication in Fertility and Sterility ... showed that the investigational compound bazedoxifene/conjugated estrogens (BZA/CE) significantly reduced ... of vaginal atrophy when compared to placebo. In this study, ...
... , , ENGLEWOOD CLIFFS, ... all regular body washes caused dry skin damage. Now, ... while cleansing with body wash. Current body washes actually damage ... to the loss of critical moisture. Recognizing skin lipids require ...
Cached Medicine Technology:Wyeth Reports Publication of Phase 3 Data for Bazedoxifene/Conjugated Estrogens, an Investigational Compound Being Studied for the Treatment of Menopausal Symptoms 2Wyeth Reports Publication of Phase 3 Data for Bazedoxifene/Conjugated Estrogens, an Investigational Compound Being Studied for the Treatment of Menopausal Symptoms 3Wyeth Reports Publication of Phase 3 Data for Bazedoxifene/Conjugated Estrogens, an Investigational Compound Being Studied for the Treatment of Menopausal Symptoms 4Wyeth Reports Publication of Phase 3 Data for Bazedoxifene/Conjugated Estrogens, an Investigational Compound Being Studied for the Treatment of Menopausal Symptoms 5Wyeth Reports Publication of Phase 3 Data for Bazedoxifene/Conjugated Estrogens, an Investigational Compound Being Studied for the Treatment of Menopausal Symptoms 6Video: New Dove(R) Body Washes with NutriumMoisture(TM) Restore Skin's Natural Moisture 2Video: New Dove(R) Body Washes with NutriumMoisture(TM) Restore Skin's Natural Moisture 3Video: New Dove(R) Body Washes with NutriumMoisture(TM) Restore Skin's Natural Moisture 4
(Date:7/30/2014)... Frozen shoulder (Adhesive capsulitis) affects 10-20 percent ... this nasty condition which occurs most frequently in people between ... to two and half years if not treated. , Adhesive ... good reason: it can render your shoulder so stiff, it's ... you aren't in too much pain to get dressed in ...
(Date:7/30/2014)... (HealthDay News) -- For patients with asthma, just believing ... airway inflammation for at least 24 hours, a new ... but also what you think you smell," study author ... in Philadelphia, said in a Monell news release. ... When we expect that an odor is harmful, our ...
(Date:7/30/2014)... vast majority of kids with autism have abnormal sensory ... children who have trouble processing sensory stimuli, researchers report. ... overly sensitive to sound, sight and touch. They can ... of concentration. Complicating matters, some kids with SPD ... tolerating loud noises, like a vacuum. Others can,t hold ...
(Date:7/30/2014)... months or more as babies have a significantly ... and metabolic diseases, according to research from the ... , "This study shows that birthweight and breastfeeding ... said Molly W. Metzger, PhD, assistant professor at ... study with Thomas W. McDade, PhD, of Northwestern ...
(Date:7/30/2014)... 2014 On July 29, 2014, Freedom ... Institute of Public Health, Gandhinagar released a new report ... II: The Way Forward .” The report was released ... and Practices to Improve Nutrition Security in New Delhi, ... the Green Revolution" and chair of the Coalition ...
Breaking Medicine News(10 mins):Health News:Good News for Diabetics Suffering from Frozen Shoulder 2Health News:Good News for Diabetics Suffering from Frozen Shoulder 3Health News:Good News for Diabetics Suffering from Frozen Shoulder 4Health News:Even Thinking an Odor is Harmful May Spur Asthma Symptoms 2Health News:Different Areas of Brain Affected in Autism, Sensory Disorders 2Health News:Different Areas of Brain Affected in Autism, Sensory Disorders 3Health News:Birthweight and breastfeeding have implications for children's health decades later 2Health News:New Report on Integrated Health and Microfinance in India Shows the Way Forward 2Health News:New Report on Integrated Health and Microfinance in India Shows the Way Forward 3Health News:New Report on Integrated Health and Microfinance in India Shows the Way Forward 4
... Woo-suk, the South Korean stem cell scientist who took the ... embryo, faked his reports that were published in the journal ... the stem cell lines used in the research paper analysis ... ones cloned by Hwang were destroyed by a virus. “Without ...
... device called Compex Motion has been developed by University of ... cord injuries walk again. The device makes the muscles// work ... ,The bursts, called functional electrical stimulation or FES, is ... the patient's movement is not dependent on the machine. ...
... British Association for Parenteral and Enteral Nutrition (BAPEN) has ... annually. This is more than twice the cost incurred ... a low priority to malnutrition, according to BAPEN. Malnutrition ... nutrients which results in the body functions being affected., ...
... people afflicted with the Alzheimer's disease is expected to rise ... in developing nations. //As of 2005, 24 million people suffer ... age, and by the year 2020, this figure is expected ... the year 2040. ,South Asia and China ...
... in the global healthcare destination of Chennai to net an ... in Kumbakonam, 350 km from here, and the offices and ... officials simultaneously. About Rs.6 million in cash as well as ... in the raids from the 30 odd locations in Chennai., ...
... called the Cone beam computerized tomography (CBCT) is increasingly ... oral problems.// ,J. Martin Palomo and Mark ... Western Reserve University School of Dental Medicine and C.H. ... health and biological sciences at the University of Wales' ...
Cached Medicine News:Health News:New Computerized Imaging Systems Help In Better Dental Treatment Planning 2
With this more compact transducer face, this is the transducer of choice for obstetric imaging in areas with a small acoustic window....
... The 9101-7.5 convex array is designed with ... resolution obtained with this multi-frequency transducer is ... in need of quick and accurate diagnoses. ... versatility you need, and allows you to ...
... The new XL3000 by ... illuminator,featuring the latest in,Cermax Xenon ... optic illumination technology,for integration into ... that require,bright, accurate color illumination.,It ...
... Test System* is a multiplexed, fluorescent, ... multiple assays from a single sample ... a simple and streamlined alternative to ... clinical sensitivity and comparable clinical specificity ...
Medicine Products: